Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older.
Wall Street, according to CNBC's Mad Money host Jim Cramer, is no longer a monolithic entity but rather a fractured landscape operating under three distinct economic realities. In recent broadcasts around October 8 and 9, 2025, Cramer articulated a vision of the market segmented into a booming Artificial Intelligence and
Investors are eagerly awaiting the start of earnings season for market direction, as the continued government shutdown is creating a lack of economic data
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 6.5% in the afternoon session after a Bank of America report highlighted weakening order trends and a lowered fourth-quarter revenue forecast.
New York, NY – October 9, 2025 – Pfizer Inc. (NYSE:PFE) has once again affirmed its steadfast commitment to shareholder returns, declaring a $0.43 per-share cash dividend for the fourth quarter of 2025. This latest payout marks a significant milestone: the company's 348th consecutive quarterly dividend. The unwavering consistency of
Eli Lilly and Company (NYSE: LLY) has announced the completion of its Phase 1 bioavailability study for the combination of Bimagrumab and Tirzepatide on October 8, 2025, a foundational step in understanding the pharmacokinetic profile of this potential therapy. While this marks a technical advancement in drug development, the news
Amazon (NASDAQ: AMZN) continues to aggressively expand its strategic business developments, solidifying its e-commerce dominance through frequent Prime discount events and making significant inroads into the pharmacy sector. These initiatives, spanning from late 2023 through 2025, are designed to strengthen customer loyalty, capture new markets, and leverage Amazon's robust logistics
